For example, in a phase 1b/2 study in NK T-cell lymphoma, the anti-PD-1 antibody sintilimab in combination with the HDAC inhibitor chidamide had an expected objective response rate of 80% [161]. The gene discussed is PDCD1; the disease is extranodal nasal NK/T cell lymphoma.